General Information of Drug (ID: DMA3Y8C)

Drug Name
Fumagillin Drug Info
Synonyms
MLS002702991; SMR001566800; NCGC00163699-01; AC1NS4EN; SCHEMBL6953272; MEGxm0_000010; CHEMBL1396346; BDBM95462; ACon0_000963; MolPort-044-567-755; cid_45281154; MolPort-001-739-223; MCULE-6695017352; NCGC00163699-03; J-014992; Fumagillin from Aspergillus fumigatus, > =90%, powder; NCGC00163699-03_C26H34O7_2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-buten-1-yl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, (2E,4E,6E,8E)-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6917655
ChEBI ID
CHEBI:48635
CAS Number
CAS 23110-15-8
TTD Drug ID
DMA3Y8C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beloranib DM71CK8 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
D-Methionine DMMKGBP N. A. N. A. Phase 3 [3]
ZGN-1061 DM9KB7A Type 2 diabetes 5A11 Phase 2 [4]
M8891 DMZ9NVP Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
SDX-7320 DMU0Q6L Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PPI-2458 DMSAQBC Autoimmune diabetes 5A10 Phase 1 [6]
TNP-470 DMT0QK8 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [7]
2-Methyl-2-Propanol DMHM5GJ Discovery agent N.A. Investigative [3]
2-(phenylsulfonamido)-5-propylbenzoic acid DMDGAHO Discovery agent N.A. Investigative [8]
5-p-Tolyl-1H-[1,2,3]triazole DM2W0AD Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Methionine aminopeptidase 2 (METAP2) TTZL0OI MAP2_HUMAN Binder [1]

References

1 Homology modeling and calculation of the cobalt cluster charges of the Encephazlitozoon cuniculi methionine aminopeptidase, a potential target for drug design. Biophys Chem. 2003 Aug 1;105(1):29-43.
2 2011 Pipeline of Zafgen.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26.
7 Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9.
8 Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
9 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J Med Chem. 2005 Sep 8;48(18):5644-7.